A single center, prospective and randomized controlled study of the efficacy and safety of MGN-3/BioBran for patients with B-cell non-Hodgkin's lymphoma after CR
Not Applicable
Recruiting
- Conditions
- B-cell non-Hodgkin's lymphoma
- Registration Number
- JPRN-UMIN000034569
- Lead Sponsor
- Japanese Red Cross Medical Center, Division of Hematology
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Not provided
Exclusion Criteria
-have immune suppressive agent, infectious diseases, or auto immune diseases -are allergic to rice bran
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Changes in the number of white blood cells, lymphocytes, T cells, B cells and Treg cells, and adverse event, after administration of MGN-3/BioBran for 12 weeks,
- Secondary Outcome Measures
Name Time Method